DrugPatentWatch Database Preview

Exelixis Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EXELIXIS INC, and when can generic versions of EXELIXIS INC drugs launch?

EXELIXIS INC has one approved drug.

There are four US patents protecting EXELIXIS INC drugs.

There are one hundred and eighteen patent family members on EXELIXIS INC drugs in twenty-eight countries and twelve supplementary protection certificates in nine countries.

Summary for Exelixis Inc

International Patents:	118
US Patents:	4
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Exelixis Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No	8,877,776		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	8,497,284
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-003	Apr 25, 2016		RX	Yes	Yes	9,724,342		Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No	8,497,284

Non-Orange Book US Patents for Exelixis Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,178,532	c-Met modulators and method of use
8,476,298	c-Met modulators and method of use
9,174,947	c-Met modulators and methods of use
2,014,155,378

International Patents for Exelixis Inc Drugs

Country	Document Number	Estimated Expiration
Japan	5677318
Australia	2010204461
Spain	2369652
South Korea	20130137586

Supplementary Protection Certificates for Exelixis Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0 50007-2014	Slovakia		PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
00678	Netherlands		PRODUCT NAME: CABOZANTINIB EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, WAARONDER FARMACEUTISCH AANVAARDBARE ZOUTEN; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
508	Luxembourg		PRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326
2014 00039	Denmark		PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Exela Holdings
• Exela Pharma Science
• Exela Pharma Scs Llc
• Exelixis